Meeting
2023 ASCO Annual Meeting
Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.
Authors
Valerie Elizabeth Crolley
UCL-University College London (United Kingdom ), London, United Kingdom
Valerie Elizabeth Crolley , Rachel Guest , Andrew David Beggs , Eleanor Jaynes , Steve Thorn , Javier Herrero , Ian Tomlinson , Juan W. Valle , John Neil Primrose , John A Bridgewater
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4019)
DOI
10.1200/JCO.2023.41.16_suppl.4019
Abstract #
4019
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2020 Genitourinary Cancers Symposium
Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer.
First Author: Abedalrhman Alkhateeb